Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2026 19:21 ET | Source: Cellectis Inc.

Cellectis publie ses résultats financiers du quatrième trimestre 2025 et de l’exercice 2025 et une mise à jour de ses activités

Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) en cours Phase 1 : 83 % d’ORR à la dose RP2D et 100 % d’ORR dans la population cible de phase 2.Population...
March 19, 2026 19:21 ET | Source: Cellectis Inc.

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update

Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became...
March 18, 2026 17:31 ET | Source: Marker Therapeutics

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in...
March 12, 2026 16:30 ET | Source: Cellectis Inc.

Cellectis publiera ses résultats financiers du quatrième trimestre et de l’année 2025 le 19 mars 2026

NEW YORK, 12 mars 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome...
March 12, 2026 16:30 ET | Source: Cellectis Inc.

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
March 04, 2026 16:30 ET | Source: Cellectis Inc.

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

PARIS, 04 mars 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de...
March 04, 2026 16:30 ET | Source: Cellectis Inc.

Monthly information on share capital and company voting rights

PARIS, March 04, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
January 28, 2026 10:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress

SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on...
January 26, 2026 07:00 ET | Source: Marker Therapeutics

Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology

HOUSTON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company with the worldwide exclusive license of Multi-Antigen Targeted T cells...
January 08, 2026 16:30 ET | Source: Cellectis Inc.

Cellectis annonce sa stratégie et ses jalons attendus en 2026

NEW YORK, 08 janv. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) (la « Société »), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière...